secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-07-20T13:03:03+00:00
Accession:  0001129928-26-000045
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncolytics Biotech receives FDA Fast Track for pelareorep in second-line anal cancer
--------------------------------------------------------------------------------

- FDA granted Fast Track for pelareorep + checkpoint inhibitor in inoperable/metastatic squamous cell anal carcinoma after prior therapy.
- GOBLET study showed ORR ~30% (vs historical ~15%), median DOR ~15.5 months, 12-month OS 82% (vs 45.7%).
- No FDA-approved therapies exist for patients progressing after first-line standard of care; estimated US market ~$1B annually.
- Third Fast Track designation in GI cancers (after KRAS-mCRC Feb 2026 and pancreatic cancer 2022).
- Company believes clear regulatory framework in place for pivotal study following April 2026 FDA meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000045/0001129928-26-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000045/oncy-20260720.htm
  HTML page:      https://secwatch.observer/filing/0001129928-26-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer